Aspirin therapy is well-accepted as an agent for the secondary prevention of cardiovascular
events and current guidelines also define a role for aspirin in primary prevention. In this …

Aims The role of aspirin in the primary prevention setting is continuously evolving. Recent
randomized trials have challenged the role of aspirin in the primary prevention setting …

Antiplatelet therapy, most notably aspirin, has been well documented to reduce risks of
subsequent cardiovascular disease (CVD) in secondary prevention, acute myocardial …

The benefits of aspirin therapy for the secondary prevention of cardiovascular disease
clearly outweigh the risks of bleeding, and low-dose aspirin is uniformly recommended in …

Aspirin is the cornerstone of the antithrombotic management of patients with established
atherosclerotic cardiovascular disease, but major guidelines provide conflicting …

Background: Coronary heart disease and cerebrovascular disease are leading causes of
death in the United States. In 2002, the US Preventive Services Task Force (USPSTF) …

Background: The use of aspirin to prevent cardiovascular disease events in patients without
a history of cardiovascular disease is controversial. Purpose: To examine the benefits and …

Background: Cardiovascular disease (CVD) is the leading cause of death in the United
States. Purpose: To update a systematic review about the benefits of aspirin for the primary …

ContextMore than 50 million US adults take aspirin regularly for long-term prevention of
cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding …

Until recently, 5 major studies have formed the basis for the use of aspirin (acetylsalicylic
acid) in primary prevention of cardiovascular (CV) events. Despite these data, the role of …